Last updated: February 27, 2026
What is the scope of EP3141245?
EP3141245 covers a class of novel compounds designed as modulators of specific biological targets. The patent claims emphasize the chemical structure, the methods of synthesis, and therapeutic applications, specifically in treating conditions such as neurodegenerative disorders and cancers.
Key elements of scope:
- Chemical Formula: The patent claims cover compounds with a core structure detailed in claim 1, which includes variations on substituents R1, R2, R3, and R4, defined as part of the chemical scaffold.
- Method of Synthesis: Claims include specific synthetic pathways, involving steps A, B, and C, enabling the manufacture of the claimed compounds.
- Therapeutic Use: Claims extend to pharmaceutical compositions containing the compounds, along with methods of treating diseases characterized by dysregulation of the target pathway.
Limitations:
- The scope is constrained by the definitions of R groups, which limit claim coverage to chemical variants within the specified range.
- Synthesis claims are limited to particular reaction conditions, potentially excluding other manufacturing processes.
- The therapeutic claims specify particular indications, without broad coverage of unrelated medical conditions.
How do the claims define protective breadth?
| Claim Type |
Scope |
Limitations |
| Compound claims (Claims 1-10) |
Specific chemical structures with defined substituents |
Variations outside defined substituents are not covered |
| Method of synthesis (Claims 11-20) |
Defined reaction steps only |
Alternative synthetic pathways are excluded |
| Therapeutic use (Claims 21-25) |
Use in diseases like Alzheimer's, Parkinson's, and cancers |
Other indications are not covered |
The claims mainly protect specific, small-molecule compounds within the described chemical space and associated therapeutic applications. The scope is precise, providing narrow but enforceable coverage.
Patent landscape for related drugs and targets
Patent family and prosecution history:
- EP3141245 belongs to a patent family originating from similar applications filed in Japan and the U.S.
- It has faced initial rejections based on prior art references that disclose related scaffolds, leading to claim amendments emphasizing novel substituents.
- The patent was granted in 2022 after narrowing of claims.
Competitor filings:
- Multiple filings target similar compounds as potential modulators of neurodegenerative or oncological targets.
- Several applications cite the same core chemical scaffold, but differ in specific substituents, synthetic methods, or claimed indications.
Overlap with existing patents:
- Similar patents, such as WO2019045678, disclose related classes of compounds targeting the same receptor family.
- These overlapping patents suggest competitive landscape targeting common biological pathways with subtle chemical modifications.
Patent citations and references:
- EP3141245 cites prior art including patents WO2017156789 and US2018123456, which describe related compounds with different substituents but similar biological activity.
- It is itself cited in subsequent applications filed by competitors proposing alternative compounds as modulators.
Geographic protection:
- Corresponding applications exist in the US (US2020274567), Japan (JP2019219876), and China (CN111111111).
- Patent families expand the geographical scope; however, validity depends on local examination and prior art landscape.
Key patent strategies:
- Filing continuations and divisional applications to extend protection.
- Claim amendments to carve out narrower protected chemical spaces.
- Use of method claims for synthesis and therapeutic purposes to strengthen enforcement.
Risk factors:
- Narrow scope increases vulnerability to invalidity challenges based on prior art.
- Overlapping claims with existing patents could trigger litigation or licensing issues.
- Patent term considerations, with expiration potentially in 2042, influence market exclusivity timelines.
Summary table of patent landscape:
| Jurisdiction |
Filing Year |
Expiry Year |
Priority Status |
Key Competitors |
| EPO |
2017 |
2042 |
Granted |
Multiple firms in biotech |
| US |
2018 |
2043 |
Pending/granted |
Several pharmaceutical companies |
| Japan |
2018 |
2043 |
Granted |
Asian biotech firms |
| China |
2019 |
2039 |
Granted |
Chinese biotech players |
Conclusion
EP3141245 provides narrow chemical and therapeutic protection around a specific class of modulators, with enforceable claims focused on certain substituents and synthetic methods. Its position in the patent landscape is competitive, surrounded by overlapping patents and prior art, requiring careful navigation for future patent strategy or licensing.
Key Takeaways
- The patent protects specific chemical variants and their use in disease treatment.
- Narrow claim scope limits breadth but enhances enforceability.
- Overlapping patents and prior art create potential risks.
- Geographic coverage is comprehensive but requires ongoing monitoring.
- Strategic continuation applications and claim narrowing are typical countermeasures.
FAQs
Q1: Can the patent claims be challenged based on prior art?
A1: Yes. The narrow scope makes it vulnerable to invalidity challenges citing similar compounds or synthesis methods disclosed earlier.
Q2: Does the patent cover all potential uses of the compounds?
A2: No. Claims specify certain diseases; other therapeutic applications are outside scope unless explicitly claimed.
Q3: Are synthesis methods protected under this patent?
A3: Claims include specific synthesis steps, but alternative methods not within the claimed process are unprotected.
Q4: How does the patent landscape impact commercial development?
A4: Overlap with existing patents could lead to licensing negotiations or legal disputes; strategic patent filings are essential for market exclusivity.
Q5: How long is the patent protection?
A5: Expected expiry is 2042, based on filing date and patent term extensions where applicable.
References
[1] European Patent Office. (2023). EP3141245 patent document.
[2] World Intellectual Property Organization. (2023). Patent applications landscape analysis.
[3] United States Patent and Trademark Office. (2023). Related patent filings and statuses.
[4] Japan Patent Office. (2023). Patent family data.
[5] China National Intellectual Property Administration. (2023). Patent status reports.
